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Abstract
Background: Several decision support tools have been developed to aid policymaking regarding the adoption of
pneumococcal conjugate vaccine (PCV) into national pediatric immunization programs. The lack of critical appraisal
of these tools makes it difficult for decision makers to understand and choose between them. With the aim to
guide policymakers on their optimal use, we compared publicly available decision-making tools in relation to their
methods, influential parameters and results.
Methods: The World Health Organization (WHO) requested access to several publicly available cost-effectiveness
(CE) tools for PCV from both public and private provenance. All tools were critically assessed according to the
WHO’s guide for economic evaluations of immunization programs. Key attributes and characteristics were
compared and a series of sensitivity analyses was performed to determine the main drivers of the results. The
results were compared based on a standardized set of input parameters and assumptions.
Results: Three cost-effectiveness modeling tools were provided, including two cohort-based (Pan-American Health
Organization (PAHO) ProVac Initiative TriVac, and PneumoADIP) and one population-based model
(GlaxoSmithKline’s SUPREMES). They all compared the introduction of PCV into national pediatric immunization
program with no PCV use. The models were different in terms of model attributes, structure, and data requirement,
but captured a similar range of diseases. Herd effects were estimated using different approaches in each model.
The main driving parameters were vaccine efficacy against pneumococcal pneumonia, vaccine price, vaccine
coverage, serotype coverage and disease burden. With a standardized set of input parameters developed for
cohort modeling, TriVac and PneumoADIP produced similar incremental costs and health outcomes, and
incremental cost-effectiveness ratios.
Conclusions: Vaccine cost (dose price and number of doses), vaccine efficacy and epidemiology of critical
endpoint (for example, incidence of pneumonia, distribution of serotypes causing pneumonia) were influential
parameters in the models we compared. Understanding the differences and similarities of such CE tools through
regular comparisons could render decision-making processes in different countries more efficient, as well as
providing guiding information for further clinical and epidemiological research. A tool comparison exercise using
standardized data sets can help model developers to be more transparent about their model structure and
assumptions and provide analysts and decision makers with a more in-depth view behind the disease dynamics.
Adherence to the WHO guide of economic evaluations of immunization programs may also facilitate this process.
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Background
The availability of a seven-valent pneumococal conju-
gate vaccine (PCV7), which is efficacious in preventing
invasive pneumococcal disease (IPD), pneumonia, and
acute otitis media (AOM) [1-3], has prompted policy-
makers to ponder whether or not this vaccine should be
included in the national immunization program. The
more recent licensure of higher valent PCV vaccines
(10-valent and 13-valent pneumococal conjugate vac-
cines) makes this a harder task still. Cost-effectiveness
(CE) analyses can be useful to aid decision making.
Numerous economic evaluation studies of PCV-7 have
been published since 2000 [4-29]. Despite the availability
of a comprehensive critical literature review [30], there
is a lack of critical review of the computational reliabil-
ity and convergent validity of accessible PCV models
[31]. Indeed, there is a constant need to verify the actual
model structures, model attributes, input parameters,
key assumptions and whether different models will pro-
duce the same outputs if standardized input parameters
are used. Moreover it is not clear what the strengths
and possible pitfalls of the available PCV7 models are
and the potential to use it for new PCV combinations.
In order to guide policymakers in particular from low-
income and middle-income countries (LMIC) on the
optimal use of decision-making tools, in 2009 the World
Health Organization (WHO) invited model developers
from both the public and private sectors to submit their
tools for a systematic comparative assessment. Rather
than having the aim of recommending a single tool, the
overall objective of the assessment was to provide deci-
sion makers with a menu of CE tools and their charac-
teristics for their optimal use for vaccine adoption
decisions.
This paper critically reviews a number of potentially
influential and accessible cost-effectiveness tools. We
assess the differences and similarities between models
and evaluate to which extent the outputs differ given
the use of standardized input parameters.
Methods
Comparison of cost-effectiveness models
Several publicly available cost-effectiveness modeling
tools with both public and private provenance were
identified through literature searches and key informants
and contacted by WHO (RH, AMH). Three models
were provided to our research team: Pan-American
Health Organization (PAHO) ProVac Initiative’s [32]
TriVac model version 108.5 developed by researchers
from London School of Hygiene and Tropical Medicine
(LSHTM) [33], the PneumoADIP model (beta version)
constructed by researchers from University of Medicine
and Dentistry New Jersey (UMDNJ) [34], and the
SUPREMES model (version 3.0, succinct Population
Research & Economic Modeling Exercise for Syn-
florix™) developed by modelers from GlaxoSmithKline
Biologicals (GSK) [35] (Table 1). The developers of the
models provided access to their tools and explained the
model framework via telephone conferences to our
research team (RH, NC). These tools are intended by
their developers to provide modeling team with prede-
fined set of parameters and mathematical algorithms
with which users can interact in order to develop their
own cost-effectiveness analyses.
We adopted the framework on infectious disease
mathematical model attributes by Kim and Goldie to
describe all three models [36]. Models were compared
in terms of structure, attributes, input parameters and
key assumptions against the WHO Guide for standardi-
zation of economic evaluations of immunization pro-
grams [37].
As models are often updated and revised, the reader
should note that for each model the August 2009 ver-
sion was reviewed.
Standardized input parameters
Despite the differences in terms of model structures and
data requirements, we attempt to use a common stan-
dardized set of input parameters regarding country
demographics, epidemiology and vaccine characteristics
in order to facilitate the comparison exercise (see Table
2). Meanwhile it should be clear that only a dataset for
a cohort model approach has been developed and not
one for a population-based model. A cohort model will
focus on the accumulated benefit over time for indivi-
duals within the cohort, whereas for a population model
the focus is on the immediate benefit across different
age cohorts making up the population at the time of the
assessment. Hence an analysis of the SUPREMES results
was difficult to assess [38]. In order to determine the
robustness of the similarities of outputs independent of
country-specific data sets, we chose to compare standar-
dized input parameters for three hypothetical but typical
countries each representing different regions: sub-
Saharan Africa (SSA), South-East Asia (SEA) and Latin
America and the Caribbean (LAC).
Sensitivity analysis
All three models have different ways of specifying values
for uncertainty and sensitivity analysis. The SUPREMES
model applies a predefined non-adjustable rule of 20%
adjustment upwards and downwards from the baseline
value. The PneumoADIP model does not allow for sensi-
tivity and/or uncertainty analysis, however it can be per-
formed by repeating the model runs for specific scenarios
with different input parameters. The PAHO TriVac model
provides the user with a default set of parameters, specify-
ing the maximum and minimal values of each parameter if
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uncertainty information from the user is lacking. We used
a series of one-way sensitivity analyses to determine the
major drivers of the models by using 20% adjustment
upward and downward for several parameters where pos-
sible and calculated the boundary values accordingly for
the different tools assessed. We adopted the hypothetical
country data from the SSA region as an example of the
sensitivity analysis in our study.
We categorized the influences of parameters on out-
puts into four groups: minimally influential (percentage
change < 5%), mildly influential (5% to 30%), moderately
influential (30% to 50%), and highly influential (> 50%).
Tornado plots, a graphical presentation of the results of
a series of sensitivity analyses, were used to help visually
determine the influential parameters. Regardless of mod-
els, parameters with at least mild influence were selected
and listed on the Y axis of tornado plots in order to
compare the influences of parameters across models. In
order to allow for direct comparisons, we chose to pre-
sent the sensitivity analysis results of PAHO TriVac
using 20% adjustment rather than the default values in
the model.
Outputs
The outputs chosen for investigation while varying input
parameters were differences in outcomes and costs as
well as an incremental cost-effectiveness ratios (ICERs).
The differences in outcome were presented as disability-
adjusted life years (DALYs) averted for the PAHO Tri-
Vac and PneumoADIP models and quality-adjusted life
years (QALYs) gained for the SUPREMES model, while
the differences in cost were expressed in US dollars (US
Table 1 Characteristics of cost-effectiveness models (PneumoADIP, Pan-American Health Organization (PAHO) TriVac,
and SUPREMES)
PneumoADIP PAHO TriVac SUPREMES
Types of
study
CEA and CUA CEA and CUA CEA and CUA
Population Number of live birth of 10 cohorts
(secular trend analysis)
Number of births 5 years prior to start of
intervention and number of live birth per
year
Cross-sectional analysis of entire population
Perspective Society Society and government Healthcare payera
Vaccination Pneumococcal Pneumococcal, Rotavirus, Hib Pneumococcalb
Outcomes Cost per DALY averted, cost per
life year saved
Cost per DALY averted, cost per life saved,
cost per life year gained, cost per case
averted, cost per hospitalization averted
Cost per QALY gained, cost per life year gained
Time
horizon
5 years 5 years Cross sectional
Diseases
captured
Pneumococcal pneumonia,
pneumococcal meningitis, invasive
NPNM, otitis media
Pneumococcal pneumonia, pneumococcal
meningitis, invasive NPNM
Pneumococcal pneumonia, pneumococcal
meningitis, pneumococcal bacteremia, otitis mediac
Herd
immunity
Included only in vaccine-targeted
cohorts; no switch ‘off’ and ‘on’
Included only in vaccine-targeted cohorts;
can be switched ‘off’ and ‘on’
Included for vaccine targeted and non-targeted
population; can be switched ‘off’ and ‘on’
Serotype
replacement
Does not allow an explicit
consideration of serotype
replacement, (allows for serotype
adjustment)
Allows for an explicit direct adjustment for
serotype replacement over time
No direct adjustment for serotype replacement over
time (the individual component of replacement is
included in the direct vaccine effectiveness
estimate)
Sequelae Pneumococcal pneumonia,
pneumococcal meningitis, invasive
NPNM
Pneumococcal pneumonia, pneumococcal
meningitis, invasive NPNM, pneumococcal
OM
Pneumococcal meningitis, pneumococcal OM (can
be switch ‘off’ and ‘on’)
Discounting 3% 3% No need for discounting
Sensitivity
analysis
NR One-way sensitivity analysisd One-way sensitivity analysise
aSpecified that the model can add the societal perspective as well when including indirect cost estimates.
bSpecified PCV as Synflorix™ (10-valent pneumococcal Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV)).
cSpecified that other sensitivity analyses including a probabilistic one were under development. Currently, we can only perform one-way sensitivity analysis of
some parameters (for example, discount, age weighted, perspective, vaccine price, percentage decline in price).
dModel has an option to include the vaccine effect in preventing otitis media due to non-typeable Haemophilus influenzae (NTHi).
eModel can vary assumptions and determine its effects on results. These assumptions changes include AOM, AOM sequelae, NTHi in invasive pneumococcal
disease (IPD), NTHi in community acquired pneumonia (CAP), herd effect, and varying vaccine coverage. The model set 20% range change under and above the
baseline values for most of the variables in the model. The model specifies probabilistic sensitivity analysis to be performed with @Risk software initiating
acceptability curve http://www.palisade.com/risk/.
AOM = acute OM; CEA = cumulative effects analysis; CUA = cost utility analysis; DALY = disability-adjusted life years; NPNM = non-pneumonia non-meningitis;
OM = otitis media; QALY = quality-adjusted life years.
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$ 2009). Similarly, the ICERs were presented as incre-
mental costs per DALY averted for the PAHO TriVac
and PneumoADIP models and as incremental costs per
QALY gained for the SUPREMES model (Table 3).
Results
Comparison of cost-effectiveness models
Model structures
Both the PneumoADIP and PAHO TriVac models are
similar as they are deterministic state-transition models.
Both models follow more than one live birth cohort
over time. The models allow individuals to enter and
exit over time, and thus these can be termed ‘open’
cohort models. This is similar to how vaccination is
likely to be implemented in cohorts over time rather
than in a single cohort (although from a decisional
point of view, this difference in approach should not
matter, as this is relevant for the budget-impact calcula-
tions, but not for the cost effectiveness). The
SUPREMES model has adopted a different approach
from the previous two models. Instead of following
cohorts over time, it assesses the impact of the vaccine
in a cross-sectional population. The developers of the
SUPREMES model view their model as a prevalence-
based and user-friendly model (succinct model). It relies
on a comprehensive, 1-year population-based, age-com-
partmental modeling exercise that essentially highlights
the potential importance of herd immunity effects.
According to the developers, the SUPREMES model and
the comprehensive model have a close match of > 95%
regarding end results. The model assumes the full
effects of vaccination on the vaccinated and unvacci-
nated population at steady state. Therefore, this model
assumes that the vaccination has been implemented in
the population for a long time and that the complete
vaccine effects have been achieved across the whole
population, such that a new post-vaccination endemic
equilibrium is reached. The evaluation is made over a 1-
year period using a prevalence-based approach for asses-
sing all costs and benefits across the whole population.
In terms of structure the three tools are static-deter-
ministic models requiring calculations based on propor-
tions similar to a decision tree approach (see Table 1).
Both the PAHO TriVac and PneumoADIP models have
a default for input values estimated based on interna-
tional sources, for example, UN population database,
WHO, WHO-CHOICE, UNICEF, Global Burden of Dis-
ease (GBD) and Domestic Household Surveys (DHS).
Table 2 Input values for standardized analysis in each hypothetical country in the sub-Saharan African (SSA) region,
Southeast Asian (SEA) region and Latin America and the Caribbean (LAC) region
Model parameters Standardized values
SSA region SEA region LAC region
Population:
Total number of birth per year 60,477 932,115 140,414
Life expectancy at birth (in years) 59.45 70.62 72.9
Burden of disease:
Incidence of pneumococcal pneumonia (per 100,000 per year) 1,793 1,793 1,771
Incidence of meningitis (per 100,000 per year) 10 10 18
Incidence of invasive NPNM (per 100,000 per year) 77 77 137
Incidence of otitis media (per 100,000 per year) 400 400 400
Case fatality rate of pneumococcal pneumonia 1 1 1.8
Case fatality rate of pneumococcal meningitis 20 20 36.8
Case fatality rate of invasive NPNM 10 10 20.46
Vaccine information:
Vaccine coverage* 89% 97% 83%
Serotype coverage of pneumococcal pneumonia 60% 60% 60%
Vaccine efficacy of pneumococcal pneumonia 97.40% 97.40% 97.40%
Vaccine efficacy of pneumococcal meningitis 97.40% 97.40% 97.40%
Vaccine efficacy of pneumococcal invasive NPNM 97.40% 97.40% 97.40%
Vaccine efficacy of otitis media 57% 57% 57%
Costing information:
Dose cost $26.35 $26.35 $26.35
Standardized input of vaccine cost (US$26.35) = £16.096 (rate US$1 = £0.61) (from http://www.xe.com/ucc/) [1-3].
NPNM = non-pneumonia non-meningitis.
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Table 3 Influencing parameters for outcome, incremental cost and incremental cost effectiveness ratio (ICER) in the models
Parameters Outcomes Incremental costs ICER
DALY averted QALY
gained
Per DALY averted Per QALY
gained
TriVac
(default)
TriVac
(± 20%)
ADIP
(± 20%)
SUPR
(± 20%)
TriVac
(default)
TriVac
(± 20%)
ADIP
(± 20%)
SUPR
(± 20%)
TriVac
(default)
TriVac
(± 20%)
ADIP
(± 20%)
SUPR
(± 20%)
Population:
Total number of births per year + + ++ 0 + + +++ ++++ + + ++
Life expectancy at birth 0 + ++ ++ 0 0 + 0 0 + ++
Under 5 years mortality per 1,000 live births 0 ++ - - 0 + - - 0 ++ -
Burden of disease:
Incidence of pneumococcal pneumonia (per 100,000
per year)
++ ++ ++ - + + ++++ - ++ ++ -
Incidence of meningitis (per 100,000 per year) ++ + + - + + + - ++ + -
Incidence of invasive NPNM (per 100,000 per year) ++ ++ + - + + + - ++ ++ -
Prevalence of bacteremia sp < 10 years (cases per year) - - - ++ - - - + - - ++
Case fatality rate of pneumococcal pneumonia 0 ++ ++ + 0 0 + 0 0 ++ +
Case fatality rate of invasive NPNM 0 ++ + ++ 0 0 + 0 0 ++ ++
Vaccine information:
Vaccine efficacy of pneumococcal pneumonia ++ ++ ++ ++ + + + + ++ ++ ++
Vaccine efficacy of pneumococcal invasive NPNM + ++ + ++ + + + + + ++ ++
Vaccine efficacy adjusted NTHi - - - ++ - - - + - - ++
Vaccine coverage + + ++ ++ + ++ ++++ +++ + + ++
Serotype coverage of pneumococcal pneumonia +++ ++ ++ + + + ++++ + +++ ++ ++
Number of doses - - - + - - - +++ - - +++
Dose cost 0 0 0 0 0 +++ ++ +++ 0 ++ ++
Other parameters:
Coverage 20 years after vaccine introduced (dose 1) + ++ - - + ++ - - + ++ -
Coverage 20 years after vaccine introduced (dose 3) + ++ - - + ++ - - + ++ -
GP visits < 10 years (AOM) - - - ++ - - - + - - ++
Proportion sp of AOM - - - ++
Probability of death - - - ++ - - - 0 - - ++
0 = no change; - = not available; + = percentage change < 5%; ++ = percentage change 5% to 30%; +++ = percentage change 30% to 50%; ++++ = percentage change > 50%.
AOM = acute otitis media; NPNM = non-pneumonia non-meningitis; NTHi = non-typeable Haemophilus influenza.
ADIP = Pneumo ADIP; SUPR = Supremes
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Model attributes
All three models allow for vaccine effectiveness adjust-
ment. All models estimate the vaccine effectiveness
based on vaccine coverage and percentage of circulating
pneumococci that are caused by the serotypes included
in the vaccine (individual or all serotypes). The PAHO
TriVac model allows for an adjustment for serotype
replacement over time, through an input parameter
representing a percentage reduction in circulating pneu-
mococci caused by vaccine serotypes. Despite no direct
adjustment for serotype replacement over time, in the
SUPREMES model the effects of serotype replacement
are combined with those of herd protection into an
input parameter expressing the overall indirect vaccine
net herd effect. The PneumoADIP model allows for ser-
otype adjustment for each disease separately (for exam-
ple, pneumococcal pneumonia, meningitis, non-
pneumococcal pneumonia).
All models claim to incorporate the herd immunity
effects using different approaches. The SUPREMES
model estimates that the incidence of vaccine type
pneumococcal-related outcomes is lowered with a cer-
tain magnitude of reduction in all age groups. This
assumes the benefits of herd immunity in both vacci-
nated (direct effects) and unvaccinated (indirect effects)
people. The PAHO TriVac model assumes indirect
effects only within the cohort that is targeted for vacci-
nation. In the cost-effectiveness results of both the
PAHO TriVac and SUPREMES models herd immunity
effects can be included or excluded. In the PneumoA-
DIP model herd effects can be included in the results
section. It should be noted that in the base-case cost-
effectiveness analysis the herd effects are not accounted
for. According to the results presented on the herd
effects in the Results section, the model estimates the
herd effects among the entire population excluding
those less than 1 year of age. The PneumoADIP model
does not allow an explicit consideration of serotype
replacement to produce net herd immunity effects.
Both the SUPREMES and the PneumoADIP models
consider sequelae due to meningitis and acute otitis
media. The PAHO TriVac model categorizes sequelae as
single and multiple sequelae, and determines the
weighted average for all single and multiple sequelae. It
also presents, based on the input values, an overall rate
and proportion of having sequelae in those with pneu-
mococcal disease.
Input parameters
Some of the requirements for input parameters are quite
similar in all three models, but nonetheless several dif-
ferences should be noted.
The assessed version of PneumoADIP model does not
include default values for disease burden estimates (inci-
dence and case-fatality rate) like the other two models.
The costing components in the PneumoADIP model
include direct medical and non-medical costs and cost
for caregivers. The PAHO TriVac model includes both
direct medical and non-medical costs and has options
for household/government expenditure by disease, by
geographical area, various settings and by outpatient
pediatric department and inpatient pediatric department.
Only direct medical costs have been included in
SUPREMES model. The PneumoADIP model takes the
perspective of society, the TriVac model takes the per-
spective of the society and government while the
SUPREMES model takes the perspective of healthcare
payer with an option to add the societal perspective.
Both of the PneumoADIP and SUPREMES models esti-
mated costs from a combination of acute care costs and
long-term sequelae costs.
Assessing differences in outputs using standardized input
parameters
We found the outputs of the similarly structured PAHO
TriVac and PneumoADIP models to be comparable in
terms of outcomes, costs, and incremental cost-effective-
ness ratio. For example, the incremental cost per DALYs
averted for the hypothetical country in the SSA region
was US$3,842 and US$3,878/DALY for the PAHO Tri-
Vac and PneumoADIP models, respectively. DALYs
averted and incremental costs per person were of the
same order of magnitude (947 and 1,254 DALYs
averted; US$60 and US$80 for TriVac and PneumoA-
DIP, respectively). All outputs for the three hypothetical
countries in the three regions are shown in Table 4.
Identifying influential parameters in the models
The TriVac and PneumoADIP models yield incremental
costs per DALY averted while the SUPREMES model
yields incremental cost per QALY gained. Furthermore
incremental costs, DALYs averted, and QALYs gained
are also reported separately (Table 3).
The PneumoADIP model for the hypothetical country
example in the SSA region proposes that the use of
PCV results both in cost savings and improved health
outcomes, and hence in this model PCV vaccination is
the dominant option versus doing nothing (resulting in
a negative ICER, which we choose not to present as it
could be misleading).
The robustness of the findings in the three models
was evaluated with a series of sensitivity analyses using
QALYs or DALYs, incremental costs and incremental
cost-effectiveness ratio as outputs and presented as tor-
nado plots (Figures 1,2,3).
Serotype coverage of pneumonia was found to be the
only parameter with moderate influence on the number
of DALYs averted in the PAHO TriVac model (Figure 1).
Parameters influencing cost outputs were varying
depending on the models (Figure 2). For the PAHO Tri-
Vac model, the vaccine dose cost was rated a
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Table 4 Outputs of all three models using standardized set of input parameters for hypothetical countries in the subA-Saharan African (SSA) region, Southeast
Asian (SEA) region and Latin America and the Caribbean (LAC) region
Hypothetical country, SSA region Hypothetical country, SEA region Hypothetical country, LAC region
Results ADIP Pan-American
Health
Organization
(PAHO) TriVac
SUPR ADIP PAHO
TriVac
SUPR ADIP PAHO
TriVac
SUPR
D S D/S D S D S D/S D S D S D/S D S
Outcomes:
Life years
gained
5,657 1,228 18,500a 1,511 1,781 109,405 22,584 295,344a 1,511 2,228 17,568 7,648 99,204a 1,511 3,847
Death averted - - 567a 18 30 - - 8,786a 18 32 - - 2,924a 18 53
QALYs gained - - 2,438 3,523 - - - 2,438 4,123 - - - 2,438 5,474
DALYs averted 5,681 1,254 18,950a - - 109,839 23,084 301,953a - - 17,640 7,761 100,736a - -
Costs (US$):
Incremental
cost per live
birth
population
-74,020 4,863,640 72,796,429 61,454,589 -36,736,421 84,234,567 83,385,318 1,025,138,030 61,454,589 40,278,151 -540,048 10,300,512 160,611,146 61,454,589 -28,181,083
Incremental
cost per person
-1.23 80 60 84 -607 90 89 55 84 43 -3.85 73 57 84 -201
Incremental
cost-
effectiveness
ratio (US$):
Incremental
cost per DALYs
averted
- 3,878 3,842 - - 767 3,612 3,395 - - - 1,327 1,594 - -
Incremental
cost per life
year gained
- 3,961 3,935 40,683 - 770 3,692 3,471 40,683 18,081 - 1,347 1,619 40,683 -
Incremental
cost per death
averted
- 127,290 - - - 25,763 123,289 - - - - 45,206 - - -
Incremental
cost per case
averted
- - 1,348 - - - 1,311 - - - - 1,324 - -
Incremental
cost per
hospitalization
averted
- - 9,278 - - - - 10,706 - - - - 9,047 - -
Incremental
cost per death
averted
- - 128,397 3,336,028 - - - 116,673 3,336,028 1,276,894 - - 54,935 3,336,028 -
Incremental
cost per QALYs
- - - 25,210 - - - - 25,210 9,770 - - - 25,210 -
Default means the outputs using the predefined model inputs. Standardized means the outputs using the standardized model input.
aPer 20 cohorts.
ADIP = Pneumo ADIP; SUPR = Supremes; D = default; S = standardized
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TriVac Model (+/-20% change)
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Figure 1 Tornado plots displaying sensitivity analysis (20% change) for TriVac model, PneumoADIP model and SUPREMES model for a
hypothetical country in the sub-Saharan Africa (SSA) region using outcomes (disability-adjusted life years (DALYs) averted for TriVac
model and PneumoADIP model, quality-adjusted life years (QALYs) gained for SUPREMES model) as an output.
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Figure 2 Tornado plots displaying sensitivity analysis (20% change) for TriVac model, PneumoADIP model and SUPREMES model for a
hypothetical country in the sub-Saharan Africa (SSA) region using incremental costs as an output.
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Figure 3 Tornado plots displaying sensitivity analysis (20% change) for TriVac model, PneumoADIP model and SUPREMES model for a
hypothetical country in the sub-Saharan Africa (SSA) region using incremental cost-effectiveness ratio as an output. For PneumoADIP
model, incremental cost-effectiveness ratio was not calculated because it was dominant strategy.
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moderately influential parameter. The total number of
births per year was rated as moderately influential for
the PneumoADIP model, while rated as highly influen-
tial for the SUPREMES model. Vaccine coverage was
highly influential for the cost outputs in the PneumoA-
DIP model and moderately influential in the SUPREMES
model. Other parameters such as serotype coverage of
pneumococcal pneumonia and incidence of pneumonia
were shown to be highly influential in the PneumoADIP
model, while moderate influence on cost output in the
SUPREMES model included vaccine dose cost and the
number of vaccine doses.
For the incremental cost-effectiveness ratio (Figure 3),
serotype coverage of pneumonia and the number of vac-
cine doses were a moderately influential parameter in
the PAHO TriVac model and SUPREMES models,
respectively.
In line with cost-effectiveness literature of immuniza-
tion programs, discounting was another influential para-
meter [39,40]. In the PAHO TriVac model, the changes
of this parameter from 0% to 3% and 10% resulted in an
important change of DALYs averted and incremental
cost per DALY averted. Note that this parameter could
not be varied in the PneumoADIP model. For the
SUPREMES model, discounting was not needed as the
population model evaluates the impact of interventions
across all ages at one cross sectional time period of 1
year [38]. Therefore, discounting was not listed as the
key influential parameter in this report as it can be var-
ied in only one model.
Discussion
To the best of our knowledge, this research work is the
first study conducted with an aim to compare accessible
models developed by both the public and private sec-
tors. This review provides insights into differences and
similarities of model attributes and key assumptions to
understand disease dynamics and key drivers of the
results. Importantly, having a full understanding why
different tools produce different results will help identify
data needs and pitfalls important to the users of such
models. Although the models we reviewed were devel-
oped to determine value for money of vaccination pro-
gram, different vaccines were assessed: PneumoADIP
assessed the CE of PCV, TriVac assessed the CE of
PCV, Haemophilus influenzae B (Hib) and rotavirus vac-
cines and SUPREMES appraised pneumococcal Haemo-
philus influenzae protein D-conjugate vaccine (PHiD-
CV).
The different model approaches translated in different
data input requirements, which made it a challenge to
use a standardized data set for the tool comparison
exercise. The incidence-based cohort approaches
adopted in the PneumoADIP and the PAHO TriVac
models are more data demanding and may be more
intuitively appealing than the SUPREMES model. The
latter model evaluates under static conditions an entire
population at specific time point using the total popula-
tion size and it specific age distribution to estimate the
impact of a new vaccine program on total population
health during a fixed time period (usually 1 year) and
therefore requires fewer data inputs. This feature makes
the SUPREMES model useful if the vaccine causes inter-
mediate and important changes to the population and if
budget-impact estimates after vaccine introduction are
of interest to the decision maker. In addition, the model
is easier use and can be applied widely to those coun-
tries with limited data but may be more difficult to jus-
tify as users would need to agree with several implicit
assumptions embedded in the modeling approach.
It is important to note that while all three models
were at an advanced stage of development at the time of
the comparison exercise, models of this kind are prone
to continued extension and elaboration, and weaknesses
or absent features listed in this article may be corrected
or improved with time. This comparison process can
serve a useful purpose in this regard, by giving modelers
the opportunity to identify key omissions and improve
the accuracy, transparency and usability of their models.
For example, since the evaluation in August 2009 the
TRIVAC model now includes otitis media outcomes,
advanced options for probabilistic sensitivity analysis
and scenario analysis, and key assumptions about wan-
ing efficacy and age-appropriate vaccination. The pre-
sent version of the PneumoADIP model allows discount
rates to be varied while GSK now has developed a
cohort-based version of the SUPREMES model to deal
with the different vaccine impact on disease events
using cohort-based or population-based model methods
[38]. In addition, while none of the three models had
been through a validation process at the time of the
comparison exercise, the TRIVAC model has since been
evaluated by an external expert panel [41]. As models
and cumulative effects analysis (CEA tools evolve con-
tinued appraisal is needed.
The differences between these models are not only
due to the approach and data requirements, but are dif-
ficult to distinguish without fully transparent user man-
uals. The TriVac model has an advanced user-friendly
and self-guided function enabling users to properly
interpret the research findings.
All three models include the possibility to incorporate
the herd immunity effects of the vaccination program,
however there are important differences in how this is
incorporated and the underlying assumptions in each
model. Herd immunity effects have already been shown
to be influential in various analyses published before
2006 [30]. However, the closely related effects of
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serotype replacement, which can partly nullify the bene-
ficial impacts of herd immunity are not taken into
account in any of these models. All three models have
shown that they acknowledge an important component
of outcome, the morbidity or health-related quality of
life, because they present the results in terms of incre-
mental costs per DALY averted (PneumoADIP and Tri-
Vac) or per QALY gained (SUPREMES).
From the user’s perspective, it is very important to be
able to identify influential parameters. A series of sensi-
tivity analyses using tornado diagrams has shown that
vaccine efficacy against pneumonia, serotype coverage
and replacement, vaccine coverage, and disease burden
parameters including incidence and case fatality of
pneumococcal diseases are the key driver of the out-
comes. Unfortunately, evidence to inform one or more
of these parameters is often lacking in low-income and
middle-income countries and frequently parameters are
populated through generalizations made using data from
industrialized countries. Vaccination costs was also a
parameter of major importance (though not included in
the standard sensitivity analyses).
The outputs for TriVac and PneumoADIP were found
to be very similar, while the outputs of the SUPREME
model were markedly different from the other two mod-
els. Given the differences in various aspects such as
parameters included in the models, the baseline value
used in the model, and model structure, it is not possi-
ble to distinguish the sources that could explain the dif-
ferences in findings. Because discounting is very
influencing in this long-term outcome modeling, the
lack of discounting in the SUPREME model could be
considered a crucial factor that might explain, to a cer-
tain extent, the differences in QALYs gained and cost
differences. To be more specific, the future outcomes
earned by cohort vaccinated previously are measured at
the same time for cohort currently being vaccinated.
Conclusions
The main aim of our comparison was not to make the
difference between models understandable to model
developers but foremost to potential users of these mod-
els at the country level. Understanding the differences
and similarities of these CE tools will enhance the
intended use of these tools by decision makers in terms
of feeling ownership of results. This structured tool
assessment exercise has shown that the models we com-
pared differed in terms of model structure and key
assumptions. Using a standardized input data set for
three PCV cost-effectiveness analysis tools revealed that
vaccine cost, efficacy and assumptions for critical clinical
endpoints are the most influential parameters. Compari-
son of CE tools should help local policymakers under-
stand the different approaches used in these models,
and their advantages and disadvantages in relation to
the data they have at their disposal to conduct and eco-
nomic analysis. For instance, due to the complex nature
of the transmission and ecology of pneumococci, many
simplifying assumptions were implicitly made about the
transmission dynamics in each of these models. All
assumptions and simplifications should be well under-
stood, and be transparent to users of such models. Mod-
els should be as transparent as possible according to the
criteria and requirements presented in the WHO CEA
guidelines [37]. By identifying the most relevant key
parameters influencing the results of these models,
country and region-specific data collection could be
focused as appropriately as possible. Priority should be
given to improve the data to inform key parameters. In
addition, efforts to improve and develop transmission
dynamic models with realistic age structures that better
describe the natural history of Streptococcus pneumoniae
infection and progression to pneumococcal disease and
capable of improved investigation of herd immunity and
serotype replacement effects are also important. Lastly,
the fact that the tools are evaluated and other tools are
publicly available enables different stakeholders to learn
from each other’s experiences. Adherence to the WHO
guide of economic evaluations of immunization pro-
grams may also facilitate this process [37].
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